

Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State

EMR200125-002 Page 499 of 658

Page 17 of 42
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₄ Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0


CONFIDENTIAL
INFORMATION

499/658

MI

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



① Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State EMR200125-002 Page 501 of 658

Merck Serono
EMR 200125-002

Page 19 of 42
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0

CONFIDENTIAL
INFORMATION

501/658

M


Levothyroxine
EMR 200125-002

Dosage Form Proportion:
State EMR200125-002 Page 502 of 658

Page 20 of 42
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0


CONFIDENTIAL
INFORMATION

502/658

M

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State EMR200125-002 Page 504 of 658

Merck Serono
EMR 200125-002

Page 22 of 42
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



①: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0

CONFIDENTIAL
INFORMATION

504/658

M

Levothyroxine
EMR 200125-002


Dosage Form Proportion: EMR200125-002 Page 505 of 658

Merck Serono
EMR 200125-002

Page 23 of 42
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0

CONFIDENTIAL
INFORMATION

505/658

M


Levothyroxine
EMR 200125-002

Dosage Form Proportion:
State EMR200125-002 Page 506 of 658

Page 24 of 42
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: :



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0

CONFIDENTIAL
INFORMATION

506/658

M

Levothyroxine
EMR 200125-002


Dosage Form Proportions: EMR200125-002 Page 507 of 658 Ions (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002

Page 25 of 42
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 111



#Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State EMR200125-002 Page 508 of 658

Merck Serono
EMR 200125-002

Page 26 of 42
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₄ Values) (Safety Population)

Subject ID/Random Number:



① Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.3.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0

CONFIDENTIAL
INFORMATION

508/658

M

Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State EMR200125-002 Page 509 of 658

Page 27 of 42

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0


CONFIDENTIAL
INFORMATION

509/658

M

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State EMR200125-002 Page 511 of 658

Merck Serono
EMR 200125-002

Page 29 of 42
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0


CONFIDENTIAL
INFORMATION

511/658

M

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1




#:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₄ Values)
(Safety Population)

Subject ID/Random Number:




④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: :




⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State EMR200125-002 Page 517 of 658

Merck Serono
EMR 200125-002

Page 35 of 42
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0


CONFIDENTIAL
INFORMATION

517/658

M

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




②: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Subject ID/Random Number:




①: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210698_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.9.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State EMR200125-002 Page 525 of 658

Merck Serono
EMR 200125-002

Page 1 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T₄ Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0


CONFIDENTIAL
INFORMATION

525/658

M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



●: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportion:
State


EMR200125-002 Page 527 of 658

Merck Serono
EMR 200125-002

Page 3 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0


CONFIDENTIAL
INFORMATION

527/658



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



Treatment: ● Treatment A ◆ Treatment B ▲ Treatment C

② Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportion:
State


EMR200125-002 Page 529 of 658

Merck Serono
EMR 200125-002

Page 5 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0

CONFIDENTIAL
INFORMATION

529/658

M


Levothyroxine
EMR 200125-002

Dosage Form Proportion: EMR200125-002 Page 530 of 658

Page 6 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T₄ Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment B ▲▲▲ Treatment C

①: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9fvi.0

CONFIDENTIAL
INFORMATION

530/658

M

Levothyroxine
EMR 200125-002


Dosage Form Proportion: EMR200125-002 Page 531 of 658

Merck Serono
EMR 200125-002

Page 7 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0


CONFIDENTIAL
INFORMATION

531/658

M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL_programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State EMR200125-002 Page 533 of 658

Merck Serono
EMR 200125-002

Page 9 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) {Safety Population}

Subject ID/Random Number:



Treatment: ● Treatment A ◆ Treatment B ▲ Treatment C

② Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0

CONFIDENTIAL
INFORMATION

533/658

M

Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State EMR200125-002 Page 534 of 658

Merck Serono
EMR 200125-002

Page 10 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Document No.0900bab8085ba9fv1.0

CONFIDENTIAL
INFORMATION

534/658

M

Levothyroxine
EMR 200125-002


Dosage Form Proportion: EMR200125-002 Page 535 of 658

Merck Serono
EMR 200125-002

Page 11 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0

CONFIDENTIAL
INFORMATION

535/658

M

Levothyroxine
EMR 200125-002


Dosage Form Proportion: EMR200125-002 Page 536 of 658

Merck Serono
EMR 200125-002

Page 12 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ♦♦♦ Treatment B ▲▲▲ Treatment C

④: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0


CONFIDENTIAL
INFORMATION

536/658

M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T₄ Values) (Safety Population)

Subject ID/Random Number: 1



Treatment: ●●● Treatment A ♦♦♦ Treatment B ▲▲▲ Treatment C

#: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.


Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number: .



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C
@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002


Dosage Form Proportion
State
EMR200125-002 Page 539 of 658

Page 15 of 42

Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number: 1




Merck Serono
EMR 200125-002

Page 16 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



Treatment: ●—●—● Treatment A

0:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2


source: listing 1e.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE 15.4.2.10.sas 10DEC2011

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.


Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T₄ Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●●● Treatment A ◆◆◆◆ Treatment B ▲▲▲▲ Treatment C

④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas


10DEC2014 00:20

EMR 200125-002

Figure 13.4.2.
(for Total T4 V)

(for Total T4 Values) (Safety Population) Subject ID/Random Number:

Subject ID/Random Number:



Treatment:  Treatment A  Treatment B  Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Subjects excluded from the population: horizontal lines represent the baseline of the respective treatments.

Treatment A: 12 tablets of 50 µg of levothyroxine.
Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002


Dosage Form Proportion: EMR200125-002 Page 544 of 658

Merck Serono
EMR 200125-002

Page 20 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T₄ Values) (Safety Population)

Subject ID/Random Number: 1



Treatment: ●●● Treatment A ♦♦♦ Treatment B ▲▲▲ Treatment C

0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Document No.0900bab8085ba9f v1.0

CONFIDENTIAL
INFORMATION

544/658

M

Levothyroxine
EMR 200125-002


Dosage Form Proportion: State
EMR200125-002 Page 545 of 658

Merck Serono
EMR 200125-002

Page 21 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number: ?



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0


CONFIDENTIAL
INFORMATION

545/658

M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ● Treatment A ◆ Treatment B ▲ Treatment C

0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.


Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ◆◆◆ Treatment B


① Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C


④: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T₄ Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C


Q: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Legend: Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C
① Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportion:
State


EMR200125-002 Page 551 of 658

Merck Serono
EMR 200125-002

Page 27 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Document No.0900bab8085ba9fv1.0

CONFIDENTIAL
INFORMATION

551/658

M

Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State EMR200125-002 Page 552 of 658

Merck Serono
EMR 200125-002

Page 28 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T₄ Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0


CONFIDENTIAL
INFORMATION

552/658

M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ● Treatment A ◆ Treatment B ▲ Treatment C

⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.


Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

① Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.


Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T₄ Values) (Safety Population)

Subject ID/Random Number:



Levothyroxine
EMR 200125-002


Dosage Form Proportion: EMR200125-002 Page 556 of 658

Merck Serono
EMR 200125-002

Page 32 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0

CONFIDENTIAL
INFORMATION

556/658

M

Levothyroxine
EMR 200125-002

Dosage Form Proportion:
State


EMR200125-002 Page 557 of 658

Merck Serono
EMR 200125-002

Page 33 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T₄ Values) (Safety Population)

Subject ID/Random Number:



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0

CONFIDENTIAL
INFORMATION

557/658

M

Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State EMR200125-002 Page 558 of 658

Merck Serono
EMR 200125-002

Page 34 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

*: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0

CONFIDENTIAL
INFORMATION

558/658

M

Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State EMR200125-002 Page 559 of 658

Merck Serono
EMR 200125-002

Page 35 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T₄ Values) (Safety Population)

Subject ID/Random Number:



Treatment: ♦♦♦ Treatment B

④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0


CONFIDENTIAL
INFORMATION

559/658

M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T₄ Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C


④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C


⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

#: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportion:
State


EMR200125-002 Page 563 of 658

Merck Serono
EMR 200125-002

Page 39 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ●●● Treatment A ♦♦♦ Treatment B ▲▲▲ Treatment C
④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0

CONFIDENTIAL
INFORMATION

563/658

M

Levothyroxine
EMR 200125-002


Dosage Form Proportion: EMR200125-002 Page 564 of 658

Merck Serono
EMR 200125-002

Page 40 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:



Treatment: ▲▲▲ Treatment C

0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0

CONFIDENTIAL
INFORMATION

564/658

M

Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State EMR200125-002 Page 565 of 658

Merck Serono
EMR 200125-002

Page 41 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



Treatment: ●●● Treatment A ♦♦♦ Treatment B ▲▲▲ Treatment C

⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0


CONFIDENTIAL
INFORMATION

565/658

M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:




Treatment: ●●● Treatment A ◆◆◆ Treatment B ▲▲▲ Treatment C

④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

10DEC2014 00:20

Subject ID/Random Number:



#: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas


10DEC2014 00:20

Merck Serono
EMR 200125-002

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

Page 2 of 42
Confidential



Levothyroxine
EMR 200125-002

Dosage Form Proportion:
State


EMR200125-002 Page 569 of 658

Merck Serono
EMR 200125-002

Page 3 of 42
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



€:Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0


CONFIDENTIAL
INFORMATION

569/658

M

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State

EMR200125-002 Page 571 of 658

Page 5 of 42
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: 1



⑥: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0

CONFIDENTIAL
INFORMATION

571/658


M

Merck Serono
EMR 200125-002

Page 6 of 42
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values)
(Safety Population)

Subject ID/Random Number:



④: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;


Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



⑥: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;


Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: :



@: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;


Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: 10



@:Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002


Dosage Form Proportion: EMR200125-002 Page 576 of 658

Merck Serono
EMR 200125-002

Page 10 of 42
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: 1



#: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0


CONFIDENTIAL
INFORMATION

576/658

M

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values)
(Safety Population)

Subject ID/Random Number:



#:Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:





Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values)
(Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL_programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20


Levothyroxine
EMR 200125-002

Dosage Form Proportion:
State EMR200125-002 Page 580 of 658

Page 14 of 42
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values)
(Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0


CONFIDENTIAL
INFORMATION

580/658

M

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: 1



①: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;


Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: :



Treatment: ●●●●● Treatment A

④: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;


Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values)
(Safety Population)

Subject ID/Random Number:



⑥: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;


Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



①: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;


Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values)
(Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;


Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: 1



Levothyroxine
EMR 200125-002


Dosage Form Proportion:
State EMR200125-002 Page 587 of 658

Merck Serono
EMR 200125-002

Page 21 of 42
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0


CONFIDENTIAL
INFORMATION

587/658

M

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values) (Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;


Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210698_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



⑥: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;


Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;


Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



⑧: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;


Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values)
(Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;


Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas


10DEC2014 00:20

Merck Serono
EMR 200125-002

Page 28 of 42
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values)
(Safety Population)

Subject ID/Random Number:



①: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL_programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20


Levothyroxine
EMR 200125-002

Dosage Form Proportion:
State EMR200125-002 Page 595 of 658

Page 29 of 42
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0


CONFIDENTIAL
INFORMATION

595/658

M

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values)
(Safety Population)

Subject ID/Random Number: [REDACTED]



@:Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002


Dosage Form Proportion: EMR200125-002 Page 597 of 658

Merck Serono
EMR 200125-002

Page 31 of 42
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values)
(Safety Population)

Subject ID/Random Number: :



#: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

10DEC2014 00:20

Document No.0900babe8085ba9f v1.0

CONFIDENTIAL
INFORMATION

597/658

M

Levothyroxine
EMR 200125-002


Dosage Form Proportion: EMR200125-002 Page 598 of 658

Merck Serono
EMR 200125-002

Page 32 of 42
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values)
(Safety Population)

Subject ID/Random Number:



◊: Subjects excluded from PK Population;

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas

10DEC2014 00:20

Document No.0900babe8085ba9fv1.0

CONFIDENTIAL
INFORMATION

598/658

M